Skip to main content
. 2017 Dec 11;131(11):1183–1194. doi: 10.1182/blood-2017-10-811224

Table 3.

AEs occurring in at least 10% of patients

AE Grade 1, n (%) Grade 2, n (%) Grade 3, n (%) Grade 4, n (%) Total, n (%)
Nausea 28 (46) 2 (3) 0 0 30 (49)
Fatigue 20 (33) 4 (7) 1 (2) 0 25 (41)
IRR 9 (15) 16 (26) 2 (3) 0 27 (44)
Pruritus 11 (18) 7 (11) 1 (2) 0 19 (31)
Diarrhea 11 (18) 4 (7) 1 (2) 0 16 (26)
Headache 11 (18) 4 (7) 0 0 15 (25)
Cough 11 (18) 2 (3) 0 0 13 (21)
Vomiting 11 (18) 2 (3) 0 0 13 (21)
Dyspnea 8 (13) 4 (7) 0 0 12 (20)
Nasal congestion 11 (18) 1 (2) 0 0 12 (20)
Pyrexia 9 (15) 3 (5) 0 0 12 (20)
Rash 9 (15) 3 (5) 0 0 12 (20)
Anxiety 7 (11) 4 (7) 0 0 11 (18)
Rash pruritic 5 (8) 6 (10) 0 0 11 (18)
Chills 8 (13) 2 (3) 0 0 10 (16)
Myalgia 4 (7) 5 (8) 1 (2) 0 10 (16)
Abdominal pain 8 (13) 1 (2) 0 0 9 (15)
Chest discomfort 5 (8) 4 (7) 0 0 9 (15)
Flushing 5 (8) 4 (7) 0 0 9 (15)
Peripheral sensory neuropathy 9 (15) 0 0 0 9 (15)
Alopecia 8 (13) 0 0 0 8 (13)
Arthralgia 5 (8) 3 (5) 0 0 8 (13)
Bone pain 5 (8) 3 (5) 0 0 8 (13)
Dizziness 7 (11) 1 (2) 0 0 8 (13)
Paresthesia 7 (11) 0 0 0 7 (11)
Constipation 4 (7) 1 (2) 1 (2) 0 6 (10)
Urticaria 2 (3) 3 (5) 1 (2) 0 6 (10)

AEs occurring before ASCT and additional salvage therapy in ≥10% of patients (n = 61) are shown.